Bridging the evidence gap in isolated proctitis: real-world evidence on medical therapies for isolated proctitis—a nation-wide analysis using data of 8346 patients from UK IBD BioResource
Crohn’s & Colitis 360 · 05.10.2026 · 8 (4)
DOI: 10.1093/crocol/otag118 ↗Kurz gefasst
Fachartikel in der Zeitschrift Crohn’s & Colitis 360, online erschienen am 23.10.2026. Verfasst von Kaung Yan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Digital Research Service, The University of Nottingham, Nottingham, United Kingdom. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Background
Isolated proctitis (IP) affects a third of patients with ulcerative colitis. The long-term effectiveness of medical therapies in IP is still unclear.
Objective
To assess the effectiveness of medical therapies in IP.
Design
A retrospective observational cohort study using data from the NIHR IBD BioResource registered between April 4, 2016, and January 3, 2025.
Results
A total of 8346 patients with IP were included. The probability of treatment escalation from 5-aminosalicylates (5-ASAs) was 11.1%, 21.5%, and 27.3% at 1, 3, and 5 years respectively. Age onset >40 years was associated with a lower risk (hazard ratio [HR] = 0.552, 95% confidence interval [CI]: 0.491-0.621) and presence of extra-intestinal manifestations (EIMs) associated with a higher risk (HR = 1.701, 95% CI: 1.432-2.020) of treatment escalation. The probability of treatment escalation from thiopurines was 14%, 24.4%, and 30.8% at 1, 3, and 5 years respectively. Montreal classification A3 (HR = 0.707, 95% CI: 0.597-0.836) and longer disease duration (HR = 0.983, 95% CI: 0.972-0.995) were associated with a lower risk, while co-diagnosis of EIM indicated a higher risk (HR = 1.513, 95% CI: 1.209-1.894) of treatment escalation. Compared to infliximab, adalimumab (odds ratio [OR] 0.537, 95% CI: 0.416-0.692) and golimumab (OR 0.361, 95% CI: 0.206-0.618) were associated with reduced odds, while anti-integrin exposure was associated with an increased odds of treatment response (OR 2.033, 95% CI: 1.529-2.720).
Conclusion
Among the available advanced therapies evaluated, anti-integrin therapy was associated with the highest treatment persistence and response rates in this real-world cohort of IP. Further clinical trials are warranted in IP.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Digital Research Service, The University of Nottingham, Nottingham, United Kingdom.
- NIHR Nottingham Biomedical Research Centre, The University of Nottingham and Nottingham University Hospitals, Nottingham, United Kingdom.
- Pfizer Ltd, Tadworth, United Kingdom.
- Queen's Medical Centre, The University of Nottingham, Nottingham, United Kingdom.
ORCID-Profile: Shellie Radford, Adam Taylor, Burak Sahin, Bamidele Famokunwa, Gordon W Moran
Förderung
- Pfizer
Zitieren
APA
Yan, K., Vuyyuru, S. K., Radford, S., Taylor, A., Sahin, B., Famokunwa, B., & Moran, G. W. (2026). Bridging the evidence gap in isolated proctitis: real-world evidence on medical therapies for isolated proctitis—a nation-wide analysis using data of 8346 patients from UK IBD BioResource. Crohn’s & Colitis 360, 8(4). https://doi.org/10.1093/crocol/otag118
Vancouver
Yan K, Vuyyuru SK, Radford S, Taylor A, Sahin B, Famokunwa B, et al. Bridging the evidence gap in isolated proctitis: real-world evidence on medical therapies for isolated proctitis—a nation-wide analysis using data of 8346 patients from UK IBD BioResource. Crohn’s & Colitis 360. 2026;8(4). doi:10.1093/crocol/otag118
BibTeX
@article{Yan2026,
author = {Yan, Kaung and Vuyyuru, Sudheer Kumar and Radford, Shellie and Taylor, Adam and Sahin, Burak and Famokunwa, Bamidele and Moran, Gordon W},
title = {Bridging the evidence gap in isolated proctitis: real-world evidence on medical therapies for isolated proctitis—a nation-wide analysis using data of 8346 patients from UK IBD BioResource},
journal = {Crohn’s & Colitis 360},
year = {2026},
volume = {8},
number = {4},
doi = {10.1093/crocol/otag118}
}
EUVIMED